Boston Scientific (BSX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Boston Scientific (BSX) closed at $61.28 in the latest trading session, marking a -2.05% move from the prior day.
In the most recent trading session, Boston Scientific (BSX) closed at $61.86, indicating a -1.17% shift from the previous trading day.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Boston Scientific has declined over 35% in six months, yet maintains double-digit growth and 28% operating margins, creating a compelling buy opportunity. BSX trades at mid-tier valuations, despite a 5-year revenue CAGR of 15.1% and EBITDA CAGR of 19%, outpacing Medtronic and Edwards Lifesciences. Growth drivers include electrophysiology, the WATCHMAN CHAMPION trial, and M&A, with the potential to expand the addressable market and sustain 11% EPS growth.
In the closing of the recent trading day, Boston Scientific (BSX) stood at $62.93, denoting a -9.02% move from the preceding trading day.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Boston Scientific Corporation (BSX) Presents at American College of Cardiology 75th Annual Scientific Session and Expo Transcript
Boston Scientific (BSX) concluded the recent trading session at $68.15, signifying a -2% move from its prior day's close.
Boston Scientific (BSX) closed the most recent trading day at $71.2, moving +2.02% from the previous trading session.
Banco Bilbao Vizcaya Argentaria S.A. raised its position in Boston Scientific Corporation (NYSE: BSX) by 194.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 104,785 shares of the medical equipment provider's stock after purchasing an additional 69,174 shares
Alliancebernstein L.P. reduced its position in Boston Scientific Corporation (NYSE: BSX) by 9.2% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,986,478 shares of the medical equipment provider's stock after selling 302,058 shares during the period. Alliancebernstein L.P. owned 0.20% of Boston Scientific